Clinical Data AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data BioSpaceThis year's American Academy of Neurology meeting included a presentation that could one day set a new treatment standard for myasthenia gravis.Clinical DataNeuroscienceRead full story pharminent April 23, 2026 (Last updated: April 23, 2026) BioSpace This year’s American Academy of Neurology meeting included a presentation that could one day set a new treatment standard for myasthenia gravis. Clinical DataNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated CareNext: Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’ Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
